Remodeling characteristics and construction of a survival prediction model based on enhancers and regulome in intestinal type gastric cancer

Xu CHEN; Zhaole CHU; Bijun QIN; Biying LIU; Xianfeng LI; Tao WANG; Wenkang LIU; Bin WANG

doi:10.16016/j.2097-0927.202309147

您当前的位置：

首页 >

文章列表页 >

Remodeling characteristics and construction of a survival prediction model based on enhancers and regulome in intestinal type gastric cancer

Basic Medicine | 更新时间：2026-01-09

- Remodeling characteristics and construction of a survival prediction model based on enhancers and regulome in intestinal type gastric cancer
- Journal of Army Medical University Vol. 46, Issue 7, Pages: 695-704(2024)
- 作者机构：
  
  1.400044 重庆，重庆大学医学院
  2.400042 重庆，陆军特色医学中心消化内科，消化系统肿瘤精准防治重庆市重点实验室
- 作者简介：
- 基金信息：
  
  the National Natural Science Foundation for Excellent Young Scientists of China(81822032);the Natural Science Foundation for Distinguished Young Scholars of Chongqing(CSTC2019JCYJJQX0027)
- DOI：10.16016/j.2097-0927.202309147
  CLC： R318.04;R394.3;R735.2
- Received：19 December 2023，
  
  Revised：2024-02-05，
  
  Published：15 April 2024
- 稿件说明：
移动端阅览
Xu CHEN, Zhaole CHU, Bijun QIN, et al. Remodeling characteristics and construction of a survival prediction model based on enhancers and regulome in intestinal type gastric cancer[J]. Journal of Army Medical University, 2024, 46(7): 695-704.
DOI：

Xu CHEN, Zhaole CHU, Bijun QIN, et al. Remodeling characteristics and construction of a survival prediction model based on enhancers and regulome in intestinal type gastric cancer[J]. Journal of Army Medical University, 2024, 46(7): 695-704. DOI： 10.16016/j.2097-0927.202309147.

摘要

目的

研究组蛋白H3K27ac修饰在肠型胃癌的全基因组分布情况，探讨其增强子及相关调控组重塑特征，建立临床预后评估模型。

方法

收集于2022年1-12月在我院消化内科就诊患者的15例肠型胃癌组织与18例正常胃黏膜组织进行靶向H3K27ac修饰的染色质靶向捕获(cleavage under targets and tagmentation，CUT&Tag)测序，采用生物信息学分析，比较两种组织H3K27ac修饰在基因组的分布差异；基于H3K27ac修饰分布特征，鉴定增强子元件，探讨增强子及相关调控组的重塑特征；采用单因素Cox和多因素Cox等回归分析方法，构建增强子相关靶基因的预后预测模型。

结果

两种组织的H3K27ac修饰的基因组分布特征无明显差异，主要位于增强子区域；与正常胃黏膜相比，肠型胃癌增强子H3K27ac修饰的整体水平更高；共鉴定出8 847个在肠型胃癌中活性增加的增强子(获得性增强子)，占所有增强子的8.3%，其可能促进胃癌细胞增殖、黏附等恶性行为；联合6个获得性增强子相关靶基因(

BHLHE

41、

CEP

97、

CHI

2、

1、

SUPT

和

TOMM

20)构建的预测模型，能够较好地推测患者总体生存期。

结论

增强子重塑是肠型胃癌显著的表观遗传学特征之一，增强子可能通过上调

MYC

、

3等基因表达促进癌细胞恶性增殖与黏附行为，并基于增强子靶基因构建预后模型。

Abstract

Objective

To explore the genome-wide distribution of histone H3K27ac in intestinal type gastric cancer

analyze remodeling features of enhancers and regulome and construct a prediction model for prognosis.

Methods

H3K27ac CUT&Tag sequencing and RNA sequencing were performed in intestinal type gastric cancer tissues from 15 patients and normal gastric mucosa tissues from 18 healthy volunteers. Bioinformatics analysis was performed to identify the differences in genome distribution of H3K27ac modifications. Based on the distribution characteristics of H3K27ac

the enhancer elements were identified and the remodeling characteristics of enhancer and related regulome were explored. The prediction model for prognosis based on enhancer related target genes was constructed by univariate Cox and multivariate Cox regression analyses.

Results

The histone H3K27ac modification was mainly distributed in the enhancer region and displayed no significant differences in the genomic distribution patterns between normal and cancer tissues. Compared with normal gastric mucosa

the level of enhancer H3K27ac modification was higher in intestinal type gastric cancer. A total of 8 847 enhancers with increased activity in intestinal type gastric cancer were identified

accounting for 8.3% of all enhancers

which might promote malignant behaviors such as proliferation and adhesion of gastric cancer cells. A prognosis-predicting model established based on a panel of 6 genes that upregulated by the acquired enhancer in cancers

which was able to predict the overall survival of patients.

Conclusion

Enhancer remodeling is one of the significant epigenetic features of intestinal type gastric cancer. These enhancers may drive malignant growth and adhesion of cancer cells by upregulating the expression of

MYC

3 and other genes. A prognosis model based on enhancer target genes is constructed.

关键词

Keywords

references

ZHENG R S, ZHANG S W, ZENG H M, et al . Cancer incidence and mortality in China, 2016[J ] . J Natl Cancer Cent, 2022, 2(1): 1-9. DOI: 10.1016/j.jncc.2022.02.002.

LAUREN P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification[J]. Acta Pathol Microbiol Scand, 1965, 64: 31-49. DOI: 10.1111/apm.1965.64.1.31.

BUSINELLO G, ANGERILLI V, PARENTE P, et al . Molecular landscapes of gastric pre-neoplastic and pre-invasive lesions[J ] . Int J Mol Sci, 2021, 22(18): 9950. DOI: 10.3390/ijms22189950.

DAWSON M A, KOUZARIDES T. Cancer epigenetics: from mechanism to therapy[J]. Cell, 2012, 150(1): 12-27. DOI: 10.1016/j.cell.2012.06.013.

ZHANG Q, CAO X T. Epigenetic remodeling in innate immunity and inflammation[J]. Annu Rev Immunol, 2021, 39: 279-311. DOI: 10.1146/annurev-immunol-093019-123619.

STILLMAN B. Histone modifications: insights into their influence on gene expression[J]. Cell, 2018, 175(1): 6-9. DOI: 10.1016/j.cell.2018.08.032.

LAWRENCE M, DAUJAT S, SCHNEIDER R. Lateral thinking: how histone modifications regulate gene expression[J]. Trends Genet, 2016, 32(1): 42-56. DOI: 10.1016/j.tig.2015.10.007.

CRAVO M, PINTO R, FIDALGO P, et al . Global DNA hypomethylation occurs in the early stages of intestinal type gastric carcinoma[J ] . Gut, 1996, 39(3): 434-438. DOI: 10.1136/gut.39.3.434.

ONG C T, CORCES V G. Enhancer function: new insights into the regulation of tissue-specific gene expression[J]. Nat Rev Genet, 2011, 12(4): 283-293. DOI: 10.1038/nrg2957.

HÖRNBLAD A, REMESEIRO S. Epigenetics, enhancer function and 3D chromatin organization in reprogramming to pluripotency[J]. Cells, 2022, 11(9): 1404. DOI: 10.3390/cells11091404.

HO S W T, SHENG T T, XING M J, et al . Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities[J ] . Gut, 2023, 72(2): 226-241. DOI: 10.1136/gutjnl-2021-326483.

KAYA-OKUR H S, JANSSENS D H, HENIKOFF J G, et al . Efficient low-cost chromatin profiling with CUT & Tag[J ] . Nat Protoc, 2020, 15(10): 3264-3283. DOI: 10.1038/s41596-020-0373-x.

LOVE M I, HUBER W, ANDERS S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2[J]. Genome Biol, 2014, 15(12): 550. DOI: 10.1186/s13059-014-0550-8.

BRIEND M, RUFIANGE A, MONCLA L H M, et al . Connectome and regulatory hubs of CAGE highly active enhancers[J ] . Sci Rep, 2023, 13(1): 5594. DOI: 10.1038/s41598-023-32669-3.

ZHOU R W, XU J, MARTIN T C, et al . A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma[J ] . Nat Commun, 2022, 13(1): 6041. DOI: 10.1038/s41467-022-33377-8.

OTASEK D, MORRIS J H, BOUÇAS J, et al . Cytoscape Automation: empowering workflow-based network analysis[J ] . Genome Biol, 2019, 20(1): 185. DOI: 10.1186/s13059-019-1758-4.

XU F, HUANG X L, LI Y Y, et al . m 6 A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD[J ] . Mol Ther Nucleic Acids, 2021, 24: 780-791. DOI: 10.1016/j.omtn.2021.04.003..

AU E H, FRANCIS A, BERNIER-JEAN A, et al . Prediction modeling-part 1: regression modeling[J ] . Kidney Int, 2020, 97(5): 877-884. DOI: 10.1016/j.kint.2020.02.007.

CHEN F, GONG X, XIA M, et al . The aging-related prognostic signature reveals the landscape of the tumor immune microenvironment in head and neck squamous cell carcinoma[J ] . Front Oncol, 2022, 12: 857994. DOI: 10.3389/fonc.2022.857994.

DE HOND A A H, STEYERBERG E W, VAN CALSTER B. Interpreting area under the receiver operating characteristic curve[J]. Lancet Digit Health, 2022, 4(12): e853-e855. DOI: 10.1016/S2589-7500(22)00188-1.

FULCO C P, NASSER J, JONES T R, et al . Activity-by-contact model of enhancer-promoter regulation from thousands of CRISPR perturbations[J ] . Nat Genet, 2019, 51(12): 1664-1669. DOI: 10.1038/s41588-019-0538-0.

NASSER J, BERGMAN D T, FULCO C P, et al . Genome-wide enhancer maps link risk variants to disease genes[J ] . Nature, 2021, 593(7858): 238-243. DOI: 10.1038/s41586-021-03446-x.

WU Y C, LV P, HAN J, et al . Enhanced serum methylated p16 DNAs is associated with the progression of gastric cancer[J ] . Int J Clin Exp Pathol, 2014, 7(4): 1553-1562.

KIM D Y, KYOON JOO J, KYU PARK Y, et al . E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis[J ] . J Surg Oncol, 2007, 96(5): 429-435. DOI: 10.1002/jso.20732.

OOI W F, XING M J, XU C, et al . Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity[J ] . Nat Commun, 2016, 7: 12983. DOI: 10.1038/ncomms12983.

LIU L L, YANG Y Z, DUAN H, et al . CHI3L2 is a novel prognostic biomarker and correlated with immune infiltrates in gliomas[J ] . Front Oncol, 2021, 11: 611038. DOI: 10.3389/fonc.2021.611038.

PUSZTAI C, YUSENKO M V, BANYAI D, et al . M2 macrophage marker chitinase 3-like 2 (CHI3L2) associates with progression of conventional renal cell carcinoma[J ] . Anticancer Res, 2019, 39(12): 6939-6943. DOI: 10.21873/anticanres.13915.

LIN Z H, ZHANG J, ZHUANG L K, et al . Establishment of a prognostic model for hepatocellular carcinoma based on bioinformatics and the role of NR6A1 in the progression of HCC[J ] . J Clin Transl Hepatol, 2022, 10(5): 901-912. DOI: 10.14218/JCTH.2022.00191.

Views

143

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Reprogramming characteristics of H3K27ac-marked enhancer in gastric intestinal metaplasia and its transcriptional regulatory mechanism

A novel estrogen receptor expression stratification (low/moderate/high) based on Chinese population provides more accurate prognosis prediction for HR⁺/HER2^- early breast cancer patients

Immunosuppressive microenvironment of TGIF1-overexpressing gastric cancers and its clinical significance

Impact of molecular heterogeneity of NPM1 mutations on prognosis of acute myeloid leukemia: a clinical report of 86 cases

Related Author

Wenkang LIU

Linyu WU

Bo YU

Zhaole CHU

Biying LIU

Xianfeng LI

Dongfeng CHEN

Tao WANG

Related Institution

The First Clinical Medical College， Lanzhou University

Department of Hematology， the Second Hospital & Clinical Medical School， Lanzhou University

Department of Hematology， Gansu Provincial Hospital

Gansu Provincial Clinical Medical Research Center for Molecular Diagnosis and Treatment of Hematological Diseases， the First Hospital， Lanzhou University

The Laboratory Center， the First Hospital， Lanzhou University

⁰